Media coverage about Alphatec (NASDAQ:ATEC) has trended somewhat positive on Thursday, Accern Sentiment Analysis reports. The research firm scores the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Alphatec earned a media sentiment score of 0.11 on Accern’s scale. Accern also assigned media coverage about the medical technology company an impact score of 46.2196875103133 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
A number of equities research analysts have recently commented on the company. ValuEngine raised Alphatec from a “strong sell” rating to a “sell” rating in a research note on Wednesday, May 2nd. Zacks Investment Research raised Alphatec from a “sell” rating to a “hold” rating in a research note on Tuesday, May 1st. Finally, HC Wainwright set a $4.00 target price on Alphatec and gave the stock a “buy” rating in a research note on Friday, May 11th.
Shares of Alphatec traded up $0.03, hitting $3.95, during trading on Thursday, Marketbeat Ratings reports. 700 shares of the company’s stock traded hands, compared to its average volume of 102,023. The company has a debt-to-equity ratio of 1.10, a current ratio of 2.63 and a quick ratio of 1.79. Alphatec has a 1 year low of $1.58 and a 1 year high of $4.27. The stock has a market capitalization of $99.64 million, a PE ratio of -10.97 and a beta of 1.24.
Alphatec (NASDAQ:ATEC) last released its quarterly earnings data on Thursday, May 10th. The medical technology company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.01). The company had revenue of $21.31 million during the quarter, compared to the consensus estimate of $24.90 million. sell-side analysts expect that Alphatec will post -0.43 EPS for the current fiscal year.
Alphatec Company Profile
Alphatec Holdings, Inc, a medical technology company, focuses on the design, development, and promotion of products for the surgical treatment of spine disorders. Its product portfolio and pipeline address the cervical, thoracolumbar, and intervertebral regions of the spine; and cover various spinal disorders and surgical procedures.
Receive News & Ratings for Alphatec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alphatec and related companies with MarketBeat.com's FREE daily email newsletter.